Therapeutics News and Research

RSS

Intarcia announces results from ITCA 650 phase 2 study on type 2 diabetes

Intarcia Therapeutics, Inc. announced that an analysis of the results of a phase 2 clinical study of ITCA 650 (continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes will be presented at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany on Wednesday, October 3, 2012.

29 Sep 2012

BioTime forms new wholly owned subsidiary

BioTime, Inc., an Alameda-based company engaged in research and development of innovative new products in the field of regenerative medicine utilizing stem cells and related technology, announced today that it has formed a new wholly owned subsidiary, BioTime Acquisition Corporation, to pursue opportunities and acquire assets and businesses in the fields of stem cells and regenerative medicine.

29 Sep 2012

Inhibiting TRPV4 protects against diet-induced obesity, inflammation and insulin resistance

Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the publication of key preclinical data demonstrating that inhibition of the Transient Receptor Potential Vanilloid (TRPV) family of ion channels - specifically TRPV4 - resulted in activation of brown/beige fat and protection from diet-induced obesity, inflammation and insulin resistance. Ember holds an exclusive option to license these TRPV4 findings and technology.

28 Sep 2012

Molecular link between thermogenesis and development of inflammation in fat cells

Flipping a newly discovered molecular switch in white fat cells enabled mice to eat a high-calorie diet without becoming obese or developing the inflammation that causes insulin resistance, report scientists from Dana-Farber Cancer Institute.

28 Sep 2012

Efavirenz drug may play a key role in brain damage

The way the body metabolizes a commonly prescribed anti-retroviral drug that is used long term by patients infected with HIV may contribute to cognitive impairment by damaging nerve cells, a new Johns Hopkins research suggests.

28 Sep 2012

Life Technologies receives FDA clearance for OpTmizer CTS T-cell expansion media

Life Technologies Corporation today announced it has received FDA 510(k) clearance for its OpTmizer CTS T-Cell Expansion Tissue Culture Medium – a reagent that is now cleared as a Class II medical device and offers cost- and time-saving advantages for transitioning studies from the research bench to clinical trials.

28 Sep 2012

Amakem commences AMA0076 Phase 2a study in glaucoma and ocular hypertension

Amakem NV, a kinase platform company focusing on ophthalmology, today announces that it has initiated a Phase 2a proof of concept study of its novel Rho Kinase (ROCK) inhibitor, AMA0076, in patients with glaucoma and ocular hypertension.

27 Sep 2012

Stealth Therapeutics announces first implantation of Invisiport device

Stealth Therapeutics Inc. announced today that its Invisiport has been implanted in a patient for the first time.

27 Sep 2012

EPO grants patent to Rexahn’s new isoquinolinamine compounds for cancer

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 2099765 to Rexahn, entitled "5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents."

27 Sep 2012

PsiOxus initiates ColoAd1 phase I/II trial in metastatic solid tumours

PsiOxus Therapeutics, Ltd. has treated the first patient in its phase I/II clinical trial of ColoAd1for the treatment of metastatic solid tumours.

26 Sep 2012

U.S. District Court rules in favor of Alnylam in patent infringement case against Tekmira

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. District Court of the District of Massachusetts has ruled in favor of Alnylam and has denied Tekmira Pharmaceuticals Corporation's motion to dismiss certain claims and motion to disqualify Alnylam's counsel in an infringement suit filed in January 2012.

26 Sep 2012

UCSD evaluates safety and tolerability of dexanabinol in Phase I brain cancer study

Researchers at University of California, San Diego Moores Cancer Center are evaluating the safety and tolerability of a synthetic cannabinoid called dexanabinol (ETS2101). Delivered as a weekly intravenous infusion, the drug is being tested in patients with all forms of brain cancer, both primary and metastatic.

26 Sep 2012

Sarawak Biodiversity Centre in Malaysia, OSU to develop and commercialize anticancer agent

The Ohio State University has signed an agreement with the Sarawak Biodiversity Centre in Malaysia to collaborate on the further development and commercialization of a promising anticancer agent derived from a tropical tree that grows on the island of Borneo.

25 Sep 2012

Lack of cytokeratin 6A may lead to eye infections

Exposed tissue surfaces, including skin and mucous membranes, are under constant threat of attack by microorganisms in the environment. The layer of cells that line these areas, known as epithelial cells, are the first line of defense against these pathogens, but the underlying molecular mechanisms that allow them to repel microbes are unknown.

25 Sep 2012

Small fragments of keratin protein in the eye play a key role in warding off pathogens

When it comes to germ-busting power, the eyes have it, according to a discovery by University of California, Berkeley, researchers that could lead to new, inexpensive antimicrobial drugs.

25 Sep 2012

New clinical trial to evaluate DEX-M74 against hereditary inclusion body myopathy

Researchers have launched a clinical trial to evaluate the drug candidate DEX-M74 as a treatment for a rare degenerative muscle disease, hereditary inclusion body myopathy (HIBM). National Institutes of Health scientists from the National Center for Advancing Translational Sciences (NCATS) and the National Human Genome Research Institute (NHGRI) will conduct the clinical trial at the NIH Clinical Center.

25 Sep 2012

PPI use linked with risk for infection in decompensated cirrhosis

Proton-pump inhibitors are associated with an increased risk for serious infections in patients with decompensated cirrhosis, research shows.

24 Sep 2012

$Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma$

Therapeutics News and Research

Intarcia announces results from ITCA 650 phase 2 study on type 2 diabetes

BioTime forms new wholly owned subsidiary

Inhibiting TRPV4 protects against diet-induced obesity, inflammation and insulin resistance

Molecular link between thermogenesis and development of inflammation in fat cells

Efavirenz drug may play a key role in brain damage

Life Technologies receives FDA clearance for OpTmizer CTS T-cell expansion media

Amakem commences AMA0076 Phase 2a study in glaucoma and ocular hypertension

Stealth Therapeutics announces first implantation of Invisiport device

EPO grants patent to Rexahn’s new isoquinolinamine compounds for cancer

PsiOxus initiates ColoAd1 phase I/II trial in metastatic solid tumours

U.S. District Court rules in favor of Alnylam in patent infringement case against Tekmira

UCSD evaluates safety and tolerability of dexanabinol in Phase I brain cancer study

Sarawak Biodiversity Centre in Malaysia, OSU to develop and commercialize anticancer agent

Lack of cytokeratin 6A may lead to eye infections

Small fragments of keratin protein in the eye play a key role in warding off pathogens

New clinical trial to evaluate DEX-M74 against hereditary inclusion body myopathy

PPI use linked with risk for infection in decompensated cirrhosis

Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma

University of Copenhagen professors receive 2012 Carlsberg Foundations Research Prize

Greenhouse-grown corn seeds could help treat lysosomal storage disease

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News